Giancarlo Ripabelli

Prof. Giancarlo Ripabelli

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
DTDomiziana Di Tella
Domiziana Di Tella
MTManuela Tamburro
Manuela Tamburro
GGGiuliana Guerrizio
Giuliana Guerrizio
IFIncoronata Fanelli
Incoronata Fanelli
MSMichela Lucia Sammarco
Michela Lucia Sammarco
GRGiancarlo Ripabelli
Giancarlo Ripabelli
Purpose: Carbapenemases-producing Klebsiella pneumoniae are challenging antimicrobial therapy of hospitalised patients, which is further complicated by colistin resistance. This study describes molecular epidemiological insights into colistin-resistant and carbapenemases-producing clinical K. pneumoniae. Patients and methods: Cultures collected from 26 hospitalised patients during 2014–2017 in the main hospital in Molise Region, central Italy, were characterized. The minimum inhibitory concentration for 19 antibiotics was determined, including carbapenems and colistin. Prevalence of resistance-associated genes was investigated through PCR, detecting blaKPC, blaGES, blaVIM, blaIMP, blaNDM, blaOXA-48, blaCTX-M, blaTEM, blaSHV, and mcr-1,2,3,4,5,6,7,8. The mgrB gene was also analysed in colistin-resistant strains by PCR and sequencing assays. K. pneumoniae were typed by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). Results: Twenty out of 26 K. pneumoniae were phenotypically resistant to carbapenems and 19 were resistant to colistin. All isolates harbored blaKPC, and blaSHV, blaTEM and blaVIM were further the most common resistance-associated genes. In colistin-resistant strains, mcr-1,2,3,4,5,6,7,8 variants were not detected, while mutations and insertion elements in mgrB were observed in 68.4% (n=13) in 31.6% (n=6) isolates, respectively. PFGE revealed 12 clusters and 18 pulsotypes at 85% and 95% cut-off, while the Sequence Types ST512 (n=13, 50%), ST101 (n=10, 38.5%), ST307 (n=2, 7.7%) plus a novel ST were detected using MLST. Conclusion: All K. pneumoniae showed a multidrug-resistant phenotype, particularly to carbapenems and colistin. According to national data, blaKPC was the prevailing carbapenemase, followed by blaVIM, while blaTEM and blaSHV were among the most frequent beta-lactamases. Consistent with previous reports in Italy, ST512 was the most common clone, particularly during 2014–15, whilst ST101 became dominant in 2016–17. Colistin resistance was mainly associated with deleterious mutations and transposon in the mgrB gene. Improvements of surveillance, compliance with infection prevention procedures and antimicrobial stewardship are essential to limit the spread of resistant K. pneumoniae.

16 February 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
Deborah TraversiDeborah Traversi
Deborah Traversi
Alessandra PullieroAlessandra Pulliero
Alessandra Pulliero
Alberto IzzottiAlberto Izzotti
Alberto Izzotti
EFElena Franchitti
Elena Franchitti
LILicia Iacoviello
Licia Iacoviello
SBStefania Boccia
Stefania Boccia
The development of high-throughput omics technologies represents an unmissable opportunity for evidence-based prevention of adverse effects on human health. However, the applicability and access to multi-omics tests are limited. In Italy, this is due to the rapid increase of knowledge and the high levels of skill and economic investment initially necessary. The fields of human genetics and public health have highlighted the relevance of an implementation strategy at a national level in Italy, including integration in sanitary regulations and governance instruments. In this review, the emerging field of public health genomics is discussed, including the polygenic scores approach, epigenetic modulation, nutrigenomics, and microbiomes implications. Moreover, the Italian state of implementation is presented. The omics sciences have important implications for the prevention of both communicable and noncommunicable diseases, especially because they can be used to assess the health status during the whole course of life. An effective population health gain is possible if omics tools are implemented for each person after a preliminary assessment of effectiveness in the medium to long term.


1 June 2015 in Comparative Immunology, Microbiology and Infectious Diseases
Verified
Journal Article
Closed access
Manuela TamburroManuela Tamburro
Manuela Tamburro
GRGiancarlo Ripabelli
Giancarlo Ripabelli
MVMonia Vitullo
Monia Vitullo
TDTimothy James Dallman
Timothy James Dallman
MPMirella Pontello
Mirella Pontello
MSMichela Lucia Sammarco
Michela Lucia Sammarco

9 March 2018 in Current Microbiology
Verified
Journal Article
Closed access
PDF file
GRGiancarlo Ripabelli
Giancarlo Ripabelli
MTManuela Tamburro
Manuela Tamburro
GGGiuliana Guerrizio
Giuliana Guerrizio
IFIncoronata Fanelli
Incoronata Fanelli
RFRomeo Flocco
Romeo Flocco
MSMichela L. Sammarco
Michela L. Sammarco

24 March 2011 in Letters in Applied Microbiology
Verified
Journal Article
Closed access
PDF file
MVM. Vitullo
M. Vitullo
GRGiancarlo Ripabelli
Giancarlo Ripabelli
IFI. Fanelli
I. Fanelli
Manuela TamburroManuela Tamburro
Manuela Tamburro
SDS. Delfine
S. Delfine
MSM.L. Sammarco
M.L. Sammarco